Stock Events

Ondine Biomedical 

$0.12
5
+$0+0% Tuesday 16:14

Statistics

Day High
0.12
Day Low
0.12
52W High
0.25
52W Low
0.12
Volume
1,000
Avg. Volume
222
Mkt Cap
27.21M
P/E Ratio
0
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OBIMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap295.34B
AbbVie operates in the pharmaceuticals sector, focusing on immunology and oncology, areas that overlap with Ondine's antimicrobial photodynamic therapy.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson, through its pharmaceutical division, competes in developing treatments that could potentially overlap with Ondine's infection prevention solutions.
Pfizer
PFE
Mkt Cap158.95B
Pfizer is involved in the development and commercialization of vaccines and drugs, including those for infections, directly competing with Ondine's focus.
Merck &
MRK
Mkt Cap320.27B
Merck is known for its strong focus on infectious diseases, directly competing with Ondine's antimicrobial therapies.
Gilead Sciences
GILD
Mkt Cap83.09B
Gilead Sciences focuses on antiviral drugs, which could be seen as alternative treatments to Ondine's photodynamic therapies for infections.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol Myers Squibb engages in biopharmaceuticals, competing in the space of innovative treatments for various diseases, including those targeted by Ondine.
AMGEN
AMGN
Mkt Cap166.77B
Amgen focuses on human therapeutics, with a broad portfolio that could compete with Ondine's therapies in certain therapeutic areas.
Novartis
NVS
Mkt Cap236.8B
Novartis focuses on a wide range of healthcare areas, including treatments for diseases that Ondine's technology targets.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca operates in several therapeutic areas, including infections, directly competing with Ondine's infection prevention and treatment technologies.
Sanofi
SNY
Mkt Cap125.78B
Sanofi focuses on healthcare solutions across a broad range of areas, including infectious diseases, making it a competitor to Ondine's technologies.

About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company's lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections. Its product pipeline also includes the development of topical antiviral therapy for the upper respiratory tract to reduce SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Show more...
CEO
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
Country
CA
ISIN
CA68234M2058
WKN
000A3C813

Listings